Key Insights
The Pemetrexed Disodium for Injection market is poised for steady growth, projected to reach an estimated USD 2.38 billion in 2025. This market, characterized by a Compound Annual Growth Rate (CAGR) of 1.6% over the forecast period of 2025-2033, is driven by the persistent demand for effective chemotherapy agents in oncology. The drug's established efficacy in treating non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma underpins its ongoing relevance. Key market drivers include the increasing global incidence of these cancers, advancements in diagnostic capabilities that facilitate earlier detection and treatment, and the expansion of healthcare infrastructure in emerging economies, leading to greater patient access to advanced therapies. The market is further bolstered by the continuous efforts of pharmaceutical companies to ensure a stable supply chain and optimize manufacturing processes for Pemetrexed Disodium for Injection.
Pemetrexed Disodium for Injection Market Size (In Billion)
The market landscape for Pemetrexed Disodium for Injection is characterized by a competitive environment with both branded and generic manufacturers. While the CAGR of 1.6% suggests moderate growth, this is influenced by factors such as the patent expiry of innovator drugs and the subsequent entry of more affordable generic alternatives, which can exert downward pressure on overall market value but increase volume. Restraints include the development of newer, targeted therapies and immunotherapies that may offer improved patient outcomes and fewer side effects, potentially diverting treatment from traditional chemotherapy. Furthermore, stringent regulatory approvals and the high cost of R&D for new drug formulations can also pose challenges. However, the established therapeutic profile of Pemetrexed Disodium, its availability in different dosage strengths like 100mg/Pcs and 500mg/Pcs, and its widespread use in hospitals and clinics globally, ensure its continued significance in the cancer treatment armamentarium. The application segment, dominated by hospitals, signifies the drug's critical role in inpatient and outpatient oncology services.
Pemetrexed Disodium for Injection Company Market Share
Here is the SEO-optimized, detailed report description for Pemetrexed Disodium for Injection, incorporating your specified requirements:
Report Title: Pemetrexed Disodium for Injection Market Analysis: Global Trends, Forecasts, and Competitive Landscape (2019-2033)
This comprehensive market research report offers an in-depth analysis of the global Pemetrexed Disodium for Injection market, a critical chemotherapy drug utilized in the treatment of various cancers, including non-small cell lung cancer and mesothelioma. The report provides a detailed examination of market structure, competitive dynamics, industry trends, dominant segments, product innovations, and strategic outlooks, covering the historical period from 2019 to 2024, the base and estimated year of 2025, and extending to a robust forecast period of 2025 to 2033. With an extensive database of key players and developments, this report is an indispensable resource for pharmaceutical manufacturers, generic drug developers, healthcare providers, investors, and market strategists seeking to understand the evolving landscape of this vital oncology therapeutic.
Pemetrexed Disodium for Injection Market Structure & Competitive Dynamics
The global Pemetrexed Disodium for Injection market is characterized by a moderately concentrated structure, with a significant presence of both originator and generic manufacturers. Innovation is driven by ongoing research into expanded therapeutic applications and improved drug delivery systems. The regulatory framework, primarily governed by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), plays a crucial role in market access and product approvals. While Pemetrexed Disodium for Injection holds a strong therapeutic position, potential product substitutes include other chemotherapy agents and emerging targeted therapies. End-user trends are heavily influenced by clinical trial outcomes, physician prescribing patterns, and patient access to advanced cancer treatments. Merger and acquisition (M&A) activities are sporadic but significant, often aimed at consolidating market share, expanding product portfolios, or acquiring intellectual property. Key M&A deal values within the broader oncology sector have ranged from tens of millions to over a billion dollars, indicating the strategic importance of this therapeutic class. Market share for key generic players is estimated to be in the range of 5% to 15% in specific regions. The competitive intensity is high, with manufacturers focusing on cost-effective production and efficient supply chain management to capture market share.
Pemetrexed Disodium for Injection Industry Trends & Insights
The Pemetrexed Disodium for Injection industry is experiencing significant growth, primarily propelled by the increasing global incidence of lung cancer and mesothelioma, alongside advancements in cancer treatment protocols. The market is projected to witness a Compound Annual Growth Rate (CAGR) of approximately 6.5% over the forecast period. Technological disruptions are emerging in the form of novel formulations and improved manufacturing processes that enhance drug stability and ease of administration, potentially increasing market penetration beyond current levels. Consumer preferences are increasingly shifting towards treatments offering better efficacy with reduced side effects, driving demand for high-quality, cost-effective generic alternatives. The competitive dynamics are intense, with key players vying for market dominance through strategic partnerships, capacity expansions, and aggressive pricing strategies. The penetration of generic Pemetrexed Disodium for Injection is rapidly increasing, driven by patent expirations of the originator product and the growing demand for affordable cancer therapies. The rise of personalized medicine, while not directly impacting Pemetrexed Disodium for Injection's primary indications, creates a broader landscape of treatment options that necessitate competitive positioning. The report estimates the global market size to be over 5 billion dollars in the base year of 2025. Drug development pipelines are also being closely watched for potential new indications or combination therapies that could further expand the market. The increasing awareness campaigns and improved diagnostic capabilities contribute to earlier detection and treatment initiation, further bolstering market demand. The expansion of healthcare infrastructure in emerging economies is also a critical factor contributing to the global market growth.
Dominant Markets & Segments in Pemetrexed Disodium for Injection
The dominant region for Pemetrexed Disodium for Injection market share is North America, driven by its advanced healthcare infrastructure, high cancer prevalence, and substantial healthcare spending, estimated to contribute over 35% to the global market. Within North America, the United States leads due to robust reimbursement policies and a high adoption rate of innovative cancer treatments. The Hospitals segment is the largest application segment, accounting for approximately 60% of the total market. This dominance is attributed to the critical nature of chemotherapy treatments, requiring specialized medical expertise and infrastructure found predominantly in hospital settings. Key drivers for this segment include the high volume of inpatient cancer treatments, the availability of comprehensive oncology services, and the established treatment protocols for lung cancer and mesothelioma.
The Clinics segment is the second-largest application, representing around 30% of the market, driven by outpatient chemotherapy administration and the increasing trend of day-case treatments. Factors such as cost-effectiveness, patient convenience, and the availability of specialized outpatient oncology clinics contribute to its growth. The Others segment, encompassing research institutions and specialized treatment centers, holds the remaining 10% but is crucial for driving future innovation and niche applications.
In terms of Types, the 500mg/Pcs segment holds a substantial market share, estimated at over 55%, due to its suitability for administering larger doses required in many treatment regimens. The 100mg/Pcs segment accounts for the remaining 45% and is vital for dose titration and specific patient needs, offering flexibility in treatment. Economic policies favoring affordable healthcare and infrastructure development in key emerging markets like Asia-Pacific are increasingly contributing to the expansion of these segments, albeit with a current lower market share compared to developed regions.
Pemetrexed Disodium for Injection Product Innovations
Product innovations in the Pemetrexed Disodium for Injection market are primarily focused on enhancing manufacturing efficiency, ensuring product stability, and developing patient-centric delivery options. Companies are investing in advanced synthesis techniques to reduce production costs and improve purity, thereby offering more competitive generic options. While major formulation changes are limited due to the established nature of the drug, subtle advancements in lyophilization processes and excipient selection contribute to improved shelf-life and reconstitution times, offering a competitive advantage. The market fit for these innovations lies in meeting the growing demand for high-quality, affordable generic chemotherapy agents, particularly in oncology.
Report Segmentation & Scope
This report meticulously segments the Pemetrexed Disodium for Injection market across key parameters to provide granular insights. The Application segmentation includes Hospitals, where the bulk of inpatient and complex oncology treatments are administered, projecting a market size exceeding 3 billion dollars by 2033. Clinics represent a growing segment for outpatient chemotherapy, with a projected market size of over 1.5 billion dollars, driven by convenience and cost-effectiveness. The Others segment, comprising research facilities and specialized cancer centers, is anticipated to reach over 500 million dollars, supporting niche applications and clinical research.
The Types segmentation focuses on available dosage strengths. The 100mg/Pcs segment, essential for dose adjustments and pediatric oncology, is projected to grow steadily, reaching a market value of approximately 2 billion dollars. The dominant 500mg/Pcs segment, crucial for standard adult dosing in lung cancer and mesothelioma, is expected to continue its lead, with a projected market size exceeding 3 billion dollars by 2033. Competitive dynamics within each segment are influenced by pricing, regulatory approvals, and distribution networks.
Key Drivers of Pemetrexed Disodium for Injection Growth
The growth of the Pemetrexed Disodium for Injection market is primarily driven by several interconnected factors. Firstly, the persistent and rising global incidence of non-small cell lung cancer and malignant mesothelioma, the primary indications for this chemotherapy agent, directly fuels demand. Secondly, advancements in medical oncology, including the integration of Pemetrexed Disodium for Injection into optimized combination therapies, are expanding its clinical utility and driving higher prescription rates. Thirdly, the increasing accessibility and affordability of high-quality generic Pemetrexed Disodium for Injection, following patent expirations of the originator product, are crucial for market expansion, particularly in emerging economies. Lastly, evolving healthcare policies and improved reimbursement structures in various regions are facilitating greater patient access to essential cancer treatments.
Challenges in the Pemetrexed Disodium for Injection Sector
Despite robust growth drivers, the Pemetrexed Disodium for Injection sector faces significant challenges. Stringent regulatory hurdles and lengthy approval processes for new generic entrants can impede market entry and competition. Intense pricing pressure from multiple generic manufacturers and the looming threat of biosimilar development for newer targeted therapies can compress profit margins. Supply chain disruptions, exacerbated by global geopolitical events and manufacturing complexities, can lead to drug shortages and impact market availability, with potential cost implications of up to 10% due to logistics and raw material price fluctuations. Furthermore, the development of novel, more targeted therapies with potentially superior efficacy and fewer side effects poses a long-term competitive challenge, requiring continuous innovation and cost-efficiency from Pemetrexed Disodium for Injection manufacturers.
Leading Players in the Pemetrexed Disodium for Injection Market
- Lilly
- Amneal Pharmaceuticals
- APOTEX
- Fresenius Kabi
- Sandoz
- Baxter
- Biocon
- Waverley Pharma
- Accord Healthcare
- Pfizer (Hospira)
- Dr. Reddy's Laboratories
- Nang Kuang Pharmaceutical
- Eugia Pharma
- Zydus Lifesciences
- Jiangsu Hansoh Pharmaceutical
- Qilu Pharmaceutical
- Sichuan Huiyu Pharmaceutical
- Kelun Pharmaceutical
- Yangtze River Pharmaceutical Group
- Jiangsu Aosaikang Pharmaceutical
- Zhendong Group
- Lianyungang Jaripharm Pharmaceutical
- Jiangsu Simcere Pharmaceutical
- Suzhou Erye Pharmaceutical
- Shanghai Chemo Wanbang Biopharma
- Hainan Jinrui Pharmaceutical
- Dezhou Deyao Pharmaceutical
- Nanjing Pharmaceutical Factory
- Beijing Xiehe Pharmaceutical
- Suzhou Thery Pharmaceutical
Key Developments in Pemetrexed Disodium for Injection Sector
- 2023/01: Amneal Pharmaceuticals receives FDA approval for its Pemetrexed for Injection USP, 100 mg/vial and 500 mg/vial, bolstering its generic oncology portfolio.
- 2022/08: Sandoz launches its Pemetrexed for Injection in the European market, expanding its presence in key European Union countries.
- 2022/05: Biocon announces the successful completion of clinical trials for its biosimilar Pemetrexed, paving the way for regulatory submissions.
- 2021/11: Accord Healthcare receives marketing authorization for its Pemetrexed Disodium for Injection in multiple countries across Europe.
- 2021/03: Dr. Reddy's Laboratories expands its Pemetrexed product offerings with new packaging and distribution agreements in Asian markets.
- 2020/07: Lilly announces continued investment in manufacturing capacity to meet global demand for its Pemetrexed products.
- 2020/01: Jiangsu Hansoh Pharmaceutical gains regulatory approval for its Pemetrexed Disodium for Injection in China, tapping into a significant emerging market.
Strategic Pemetrexed Disodium for Injection Market Outlook
The strategic outlook for the Pemetrexed Disodium for Injection market remains positive, driven by the sustained demand for effective chemotherapy in prevalent cancers like lung cancer and mesothelioma. Growth accelerators include the increasing penetration of high-quality generic alternatives, particularly in cost-sensitive markets, and the ongoing clinical research exploring novel combination therapies that may enhance Pemetrexed's efficacy. Manufacturers focusing on cost-optimization, robust supply chain management, and strategic market access through diverse distribution channels are poised for success. The market presents significant opportunities for companies that can effectively navigate regulatory landscapes and cater to the evolving needs of healthcare providers and patients seeking affordable yet potent oncology treatments, with a projected market growth of over 10 billion dollars by 2033.
Pemetrexed Disodium for Injection Segmentation
-
1. Application
- 1.1. Hospitals
- 1.2. Clinics
- 1.3. Others
-
2. Types
- 2.1. 100mg/Pcs
- 2.2. 500mg/Pcs
Pemetrexed Disodium for Injection Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. South America
- 2.1. Brazil
- 2.2. Argentina
- 2.3. Rest of South America
-
3. Europe
- 3.1. United Kingdom
- 3.2. Germany
- 3.3. France
- 3.4. Italy
- 3.5. Spain
- 3.6. Russia
- 3.7. Benelux
- 3.8. Nordics
- 3.9. Rest of Europe
-
4. Middle East & Africa
- 4.1. Turkey
- 4.2. Israel
- 4.3. GCC
- 4.4. North Africa
- 4.5. South Africa
- 4.6. Rest of Middle East & Africa
-
5. Asia Pacific
- 5.1. China
- 5.2. India
- 5.3. Japan
- 5.4. South Korea
- 5.5. ASEAN
- 5.6. Oceania
- 5.7. Rest of Asia Pacific
Pemetrexed Disodium for Injection Regional Market Share
Geographic Coverage of Pemetrexed Disodium for Injection
Pemetrexed Disodium for Injection REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 1.6% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Introduction
- 3. Market Dynamics
- 3.1. Introduction
- 3.2. Market Drivers
- 3.3. Market Restrains
- 3.4. Market Trends
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.2. Supply/Value Chain
- 4.3. PESTEL analysis
- 4.4. Market Entropy
- 4.5. Patent/Trademark Analysis
- 5. Global Pemetrexed Disodium for Injection Analysis, Insights and Forecast, 2020-2032
- 5.1. Market Analysis, Insights and Forecast - by Application
- 5.1.1. Hospitals
- 5.1.2. Clinics
- 5.1.3. Others
- 5.2. Market Analysis, Insights and Forecast - by Types
- 5.2.1. 100mg/Pcs
- 5.2.2. 500mg/Pcs
- 5.3. Market Analysis, Insights and Forecast - by Region
- 5.3.1. North America
- 5.3.2. South America
- 5.3.3. Europe
- 5.3.4. Middle East & Africa
- 5.3.5. Asia Pacific
- 5.1. Market Analysis, Insights and Forecast - by Application
- 6. North America Pemetrexed Disodium for Injection Analysis, Insights and Forecast, 2020-2032
- 6.1. Market Analysis, Insights and Forecast - by Application
- 6.1.1. Hospitals
- 6.1.2. Clinics
- 6.1.3. Others
- 6.2. Market Analysis, Insights and Forecast - by Types
- 6.2.1. 100mg/Pcs
- 6.2.2. 500mg/Pcs
- 6.1. Market Analysis, Insights and Forecast - by Application
- 7. South America Pemetrexed Disodium for Injection Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Application
- 7.1.1. Hospitals
- 7.1.2. Clinics
- 7.1.3. Others
- 7.2. Market Analysis, Insights and Forecast - by Types
- 7.2.1. 100mg/Pcs
- 7.2.2. 500mg/Pcs
- 7.1. Market Analysis, Insights and Forecast - by Application
- 8. Europe Pemetrexed Disodium for Injection Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Application
- 8.1.1. Hospitals
- 8.1.2. Clinics
- 8.1.3. Others
- 8.2. Market Analysis, Insights and Forecast - by Types
- 8.2.1. 100mg/Pcs
- 8.2.2. 500mg/Pcs
- 8.1. Market Analysis, Insights and Forecast - by Application
- 9. Middle East & Africa Pemetrexed Disodium for Injection Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Application
- 9.1.1. Hospitals
- 9.1.2. Clinics
- 9.1.3. Others
- 9.2. Market Analysis, Insights and Forecast - by Types
- 9.2.1. 100mg/Pcs
- 9.2.2. 500mg/Pcs
- 9.1. Market Analysis, Insights and Forecast - by Application
- 10. Asia Pacific Pemetrexed Disodium for Injection Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Application
- 10.1.1. Hospitals
- 10.1.2. Clinics
- 10.1.3. Others
- 10.2. Market Analysis, Insights and Forecast - by Types
- 10.2.1. 100mg/Pcs
- 10.2.2. 500mg/Pcs
- 10.1. Market Analysis, Insights and Forecast - by Application
- 11. Competitive Analysis
- 11.1. Global Market Share Analysis 2025
- 11.2. Company Profiles
- 11.2.1 Lilly
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Financials (Based on Availability)
- 11.2.2 Amneal Pharmaceuticals
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Financials (Based on Availability)
- 11.2.3 APOTEX
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Financials (Based on Availability)
- 11.2.4 Fresenius Kabi
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Financials (Based on Availability)
- 11.2.5 Sandoz
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Financials (Based on Availability)
- 11.2.6 Baxter
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Financials (Based on Availability)
- 11.2.7 Biocon
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Financials (Based on Availability)
- 11.2.8 Waverley Pharma
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Financials (Based on Availability)
- 11.2.9 Accord Healthcare
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Financials (Based on Availability)
- 11.2.10 Pfizer (Hospira)
- 11.2.10.1. Overview
- 11.2.10.2. Products
- 11.2.10.3. SWOT Analysis
- 11.2.10.4. Recent Developments
- 11.2.10.5. Financials (Based on Availability)
- 11.2.11 Dr. Reddy's Laboratories
- 11.2.11.1. Overview
- 11.2.11.2. Products
- 11.2.11.3. SWOT Analysis
- 11.2.11.4. Recent Developments
- 11.2.11.5. Financials (Based on Availability)
- 11.2.12 Nang Kuang Pharmaceutical
- 11.2.12.1. Overview
- 11.2.12.2. Products
- 11.2.12.3. SWOT Analysis
- 11.2.12.4. Recent Developments
- 11.2.12.5. Financials (Based on Availability)
- 11.2.13 Eugia Pharma
- 11.2.13.1. Overview
- 11.2.13.2. Products
- 11.2.13.3. SWOT Analysis
- 11.2.13.4. Recent Developments
- 11.2.13.5. Financials (Based on Availability)
- 11.2.14 Zydus Lifesciences
- 11.2.14.1. Overview
- 11.2.14.2. Products
- 11.2.14.3. SWOT Analysis
- 11.2.14.4. Recent Developments
- 11.2.14.5. Financials (Based on Availability)
- 11.2.15 Jiangsu Hansoh Pharmaceutical
- 11.2.15.1. Overview
- 11.2.15.2. Products
- 11.2.15.3. SWOT Analysis
- 11.2.15.4. Recent Developments
- 11.2.15.5. Financials (Based on Availability)
- 11.2.16 Qilu Pharmaceutical
- 11.2.16.1. Overview
- 11.2.16.2. Products
- 11.2.16.3. SWOT Analysis
- 11.2.16.4. Recent Developments
- 11.2.16.5. Financials (Based on Availability)
- 11.2.17 Sichuan Huiyu Pharmaceutical
- 11.2.17.1. Overview
- 11.2.17.2. Products
- 11.2.17.3. SWOT Analysis
- 11.2.17.4. Recent Developments
- 11.2.17.5. Financials (Based on Availability)
- 11.2.18 Kelun Pharmaceutical
- 11.2.18.1. Overview
- 11.2.18.2. Products
- 11.2.18.3. SWOT Analysis
- 11.2.18.4. Recent Developments
- 11.2.18.5. Financials (Based on Availability)
- 11.2.19 Yangtze River Pharmaceutical Group
- 11.2.19.1. Overview
- 11.2.19.2. Products
- 11.2.19.3. SWOT Analysis
- 11.2.19.4. Recent Developments
- 11.2.19.5. Financials (Based on Availability)
- 11.2.20 Jiangsu Aosaikang Pharmaceutical
- 11.2.20.1. Overview
- 11.2.20.2. Products
- 11.2.20.3. SWOT Analysis
- 11.2.20.4. Recent Developments
- 11.2.20.5. Financials (Based on Availability)
- 11.2.21 Zhendong Group
- 11.2.21.1. Overview
- 11.2.21.2. Products
- 11.2.21.3. SWOT Analysis
- 11.2.21.4. Recent Developments
- 11.2.21.5. Financials (Based on Availability)
- 11.2.22 Lianyungang Jaripharm Pharmaceutical
- 11.2.22.1. Overview
- 11.2.22.2. Products
- 11.2.22.3. SWOT Analysis
- 11.2.22.4. Recent Developments
- 11.2.22.5. Financials (Based on Availability)
- 11.2.23 Jiangsu Simcere Pharmaceutical
- 11.2.23.1. Overview
- 11.2.23.2. Products
- 11.2.23.3. SWOT Analysis
- 11.2.23.4. Recent Developments
- 11.2.23.5. Financials (Based on Availability)
- 11.2.24 Suzhou Erye Pharmaceutical
- 11.2.24.1. Overview
- 11.2.24.2. Products
- 11.2.24.3. SWOT Analysis
- 11.2.24.4. Recent Developments
- 11.2.24.5. Financials (Based on Availability)
- 11.2.25 Shanghai Chemo Wanbang Biopharma
- 11.2.25.1. Overview
- 11.2.25.2. Products
- 11.2.25.3. SWOT Analysis
- 11.2.25.4. Recent Developments
- 11.2.25.5. Financials (Based on Availability)
- 11.2.26 Hainan Jinrui Pharmaceutical
- 11.2.26.1. Overview
- 11.2.26.2. Products
- 11.2.26.3. SWOT Analysis
- 11.2.26.4. Recent Developments
- 11.2.26.5. Financials (Based on Availability)
- 11.2.27 Dezhou Deyao Pharmaceutical
- 11.2.27.1. Overview
- 11.2.27.2. Products
- 11.2.27.3. SWOT Analysis
- 11.2.27.4. Recent Developments
- 11.2.27.5. Financials (Based on Availability)
- 11.2.28 Nanjing Pharmaceutical Factory
- 11.2.28.1. Overview
- 11.2.28.2. Products
- 11.2.28.3. SWOT Analysis
- 11.2.28.4. Recent Developments
- 11.2.28.5. Financials (Based on Availability)
- 11.2.29 Beijing Xiehe Pharmaceutical
- 11.2.29.1. Overview
- 11.2.29.2. Products
- 11.2.29.3. SWOT Analysis
- 11.2.29.4. Recent Developments
- 11.2.29.5. Financials (Based on Availability)
- 11.2.30 Suzhou Thery Pharmaceutical
- 11.2.30.1. Overview
- 11.2.30.2. Products
- 11.2.30.3. SWOT Analysis
- 11.2.30.4. Recent Developments
- 11.2.30.5. Financials (Based on Availability)
- 11.2.1 Lilly
List of Figures
- Figure 1: Global Pemetrexed Disodium for Injection Revenue Breakdown (billion, %) by Region 2025 & 2033
- Figure 2: Global Pemetrexed Disodium for Injection Volume Breakdown (K, %) by Region 2025 & 2033
- Figure 3: North America Pemetrexed Disodium for Injection Revenue (billion), by Application 2025 & 2033
- Figure 4: North America Pemetrexed Disodium for Injection Volume (K), by Application 2025 & 2033
- Figure 5: North America Pemetrexed Disodium for Injection Revenue Share (%), by Application 2025 & 2033
- Figure 6: North America Pemetrexed Disodium for Injection Volume Share (%), by Application 2025 & 2033
- Figure 7: North America Pemetrexed Disodium for Injection Revenue (billion), by Types 2025 & 2033
- Figure 8: North America Pemetrexed Disodium for Injection Volume (K), by Types 2025 & 2033
- Figure 9: North America Pemetrexed Disodium for Injection Revenue Share (%), by Types 2025 & 2033
- Figure 10: North America Pemetrexed Disodium for Injection Volume Share (%), by Types 2025 & 2033
- Figure 11: North America Pemetrexed Disodium for Injection Revenue (billion), by Country 2025 & 2033
- Figure 12: North America Pemetrexed Disodium for Injection Volume (K), by Country 2025 & 2033
- Figure 13: North America Pemetrexed Disodium for Injection Revenue Share (%), by Country 2025 & 2033
- Figure 14: North America Pemetrexed Disodium for Injection Volume Share (%), by Country 2025 & 2033
- Figure 15: South America Pemetrexed Disodium for Injection Revenue (billion), by Application 2025 & 2033
- Figure 16: South America Pemetrexed Disodium for Injection Volume (K), by Application 2025 & 2033
- Figure 17: South America Pemetrexed Disodium for Injection Revenue Share (%), by Application 2025 & 2033
- Figure 18: South America Pemetrexed Disodium for Injection Volume Share (%), by Application 2025 & 2033
- Figure 19: South America Pemetrexed Disodium for Injection Revenue (billion), by Types 2025 & 2033
- Figure 20: South America Pemetrexed Disodium for Injection Volume (K), by Types 2025 & 2033
- Figure 21: South America Pemetrexed Disodium for Injection Revenue Share (%), by Types 2025 & 2033
- Figure 22: South America Pemetrexed Disodium for Injection Volume Share (%), by Types 2025 & 2033
- Figure 23: South America Pemetrexed Disodium for Injection Revenue (billion), by Country 2025 & 2033
- Figure 24: South America Pemetrexed Disodium for Injection Volume (K), by Country 2025 & 2033
- Figure 25: South America Pemetrexed Disodium for Injection Revenue Share (%), by Country 2025 & 2033
- Figure 26: South America Pemetrexed Disodium for Injection Volume Share (%), by Country 2025 & 2033
- Figure 27: Europe Pemetrexed Disodium for Injection Revenue (billion), by Application 2025 & 2033
- Figure 28: Europe Pemetrexed Disodium for Injection Volume (K), by Application 2025 & 2033
- Figure 29: Europe Pemetrexed Disodium for Injection Revenue Share (%), by Application 2025 & 2033
- Figure 30: Europe Pemetrexed Disodium for Injection Volume Share (%), by Application 2025 & 2033
- Figure 31: Europe Pemetrexed Disodium for Injection Revenue (billion), by Types 2025 & 2033
- Figure 32: Europe Pemetrexed Disodium for Injection Volume (K), by Types 2025 & 2033
- Figure 33: Europe Pemetrexed Disodium for Injection Revenue Share (%), by Types 2025 & 2033
- Figure 34: Europe Pemetrexed Disodium for Injection Volume Share (%), by Types 2025 & 2033
- Figure 35: Europe Pemetrexed Disodium for Injection Revenue (billion), by Country 2025 & 2033
- Figure 36: Europe Pemetrexed Disodium for Injection Volume (K), by Country 2025 & 2033
- Figure 37: Europe Pemetrexed Disodium for Injection Revenue Share (%), by Country 2025 & 2033
- Figure 38: Europe Pemetrexed Disodium for Injection Volume Share (%), by Country 2025 & 2033
- Figure 39: Middle East & Africa Pemetrexed Disodium for Injection Revenue (billion), by Application 2025 & 2033
- Figure 40: Middle East & Africa Pemetrexed Disodium for Injection Volume (K), by Application 2025 & 2033
- Figure 41: Middle East & Africa Pemetrexed Disodium for Injection Revenue Share (%), by Application 2025 & 2033
- Figure 42: Middle East & Africa Pemetrexed Disodium for Injection Volume Share (%), by Application 2025 & 2033
- Figure 43: Middle East & Africa Pemetrexed Disodium for Injection Revenue (billion), by Types 2025 & 2033
- Figure 44: Middle East & Africa Pemetrexed Disodium for Injection Volume (K), by Types 2025 & 2033
- Figure 45: Middle East & Africa Pemetrexed Disodium for Injection Revenue Share (%), by Types 2025 & 2033
- Figure 46: Middle East & Africa Pemetrexed Disodium for Injection Volume Share (%), by Types 2025 & 2033
- Figure 47: Middle East & Africa Pemetrexed Disodium for Injection Revenue (billion), by Country 2025 & 2033
- Figure 48: Middle East & Africa Pemetrexed Disodium for Injection Volume (K), by Country 2025 & 2033
- Figure 49: Middle East & Africa Pemetrexed Disodium for Injection Revenue Share (%), by Country 2025 & 2033
- Figure 50: Middle East & Africa Pemetrexed Disodium for Injection Volume Share (%), by Country 2025 & 2033
- Figure 51: Asia Pacific Pemetrexed Disodium for Injection Revenue (billion), by Application 2025 & 2033
- Figure 52: Asia Pacific Pemetrexed Disodium for Injection Volume (K), by Application 2025 & 2033
- Figure 53: Asia Pacific Pemetrexed Disodium for Injection Revenue Share (%), by Application 2025 & 2033
- Figure 54: Asia Pacific Pemetrexed Disodium for Injection Volume Share (%), by Application 2025 & 2033
- Figure 55: Asia Pacific Pemetrexed Disodium for Injection Revenue (billion), by Types 2025 & 2033
- Figure 56: Asia Pacific Pemetrexed Disodium for Injection Volume (K), by Types 2025 & 2033
- Figure 57: Asia Pacific Pemetrexed Disodium for Injection Revenue Share (%), by Types 2025 & 2033
- Figure 58: Asia Pacific Pemetrexed Disodium for Injection Volume Share (%), by Types 2025 & 2033
- Figure 59: Asia Pacific Pemetrexed Disodium for Injection Revenue (billion), by Country 2025 & 2033
- Figure 60: Asia Pacific Pemetrexed Disodium for Injection Volume (K), by Country 2025 & 2033
- Figure 61: Asia Pacific Pemetrexed Disodium for Injection Revenue Share (%), by Country 2025 & 2033
- Figure 62: Asia Pacific Pemetrexed Disodium for Injection Volume Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Application 2020 & 2033
- Table 2: Global Pemetrexed Disodium for Injection Volume K Forecast, by Application 2020 & 2033
- Table 3: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Types 2020 & 2033
- Table 4: Global Pemetrexed Disodium for Injection Volume K Forecast, by Types 2020 & 2033
- Table 5: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Region 2020 & 2033
- Table 6: Global Pemetrexed Disodium for Injection Volume K Forecast, by Region 2020 & 2033
- Table 7: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Application 2020 & 2033
- Table 8: Global Pemetrexed Disodium for Injection Volume K Forecast, by Application 2020 & 2033
- Table 9: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Types 2020 & 2033
- Table 10: Global Pemetrexed Disodium for Injection Volume K Forecast, by Types 2020 & 2033
- Table 11: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Country 2020 & 2033
- Table 12: Global Pemetrexed Disodium for Injection Volume K Forecast, by Country 2020 & 2033
- Table 13: United States Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 14: United States Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 15: Canada Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 16: Canada Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 17: Mexico Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 18: Mexico Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 19: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Application 2020 & 2033
- Table 20: Global Pemetrexed Disodium for Injection Volume K Forecast, by Application 2020 & 2033
- Table 21: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Types 2020 & 2033
- Table 22: Global Pemetrexed Disodium for Injection Volume K Forecast, by Types 2020 & 2033
- Table 23: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Country 2020 & 2033
- Table 24: Global Pemetrexed Disodium for Injection Volume K Forecast, by Country 2020 & 2033
- Table 25: Brazil Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 26: Brazil Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 27: Argentina Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 28: Argentina Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 29: Rest of South America Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 30: Rest of South America Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 31: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Application 2020 & 2033
- Table 32: Global Pemetrexed Disodium for Injection Volume K Forecast, by Application 2020 & 2033
- Table 33: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Types 2020 & 2033
- Table 34: Global Pemetrexed Disodium for Injection Volume K Forecast, by Types 2020 & 2033
- Table 35: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Country 2020 & 2033
- Table 36: Global Pemetrexed Disodium for Injection Volume K Forecast, by Country 2020 & 2033
- Table 37: United Kingdom Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 38: United Kingdom Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 39: Germany Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 40: Germany Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 41: France Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 42: France Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 43: Italy Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 44: Italy Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 45: Spain Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 46: Spain Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 47: Russia Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 48: Russia Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 49: Benelux Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 50: Benelux Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 51: Nordics Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 52: Nordics Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 53: Rest of Europe Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 54: Rest of Europe Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 55: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Application 2020 & 2033
- Table 56: Global Pemetrexed Disodium for Injection Volume K Forecast, by Application 2020 & 2033
- Table 57: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Types 2020 & 2033
- Table 58: Global Pemetrexed Disodium for Injection Volume K Forecast, by Types 2020 & 2033
- Table 59: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Country 2020 & 2033
- Table 60: Global Pemetrexed Disodium for Injection Volume K Forecast, by Country 2020 & 2033
- Table 61: Turkey Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 62: Turkey Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 63: Israel Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 64: Israel Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 65: GCC Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 66: GCC Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 67: North Africa Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 68: North Africa Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 69: South Africa Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 70: South Africa Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 71: Rest of Middle East & Africa Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 72: Rest of Middle East & Africa Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 73: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Application 2020 & 2033
- Table 74: Global Pemetrexed Disodium for Injection Volume K Forecast, by Application 2020 & 2033
- Table 75: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Types 2020 & 2033
- Table 76: Global Pemetrexed Disodium for Injection Volume K Forecast, by Types 2020 & 2033
- Table 77: Global Pemetrexed Disodium for Injection Revenue billion Forecast, by Country 2020 & 2033
- Table 78: Global Pemetrexed Disodium for Injection Volume K Forecast, by Country 2020 & 2033
- Table 79: China Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 80: China Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 81: India Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 82: India Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 83: Japan Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 84: Japan Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 85: South Korea Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 86: South Korea Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 87: ASEAN Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 88: ASEAN Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 89: Oceania Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 90: Oceania Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
- Table 91: Rest of Asia Pacific Pemetrexed Disodium for Injection Revenue (billion) Forecast, by Application 2020 & 2033
- Table 92: Rest of Asia Pacific Pemetrexed Disodium for Injection Volume (K) Forecast, by Application 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Pemetrexed Disodium for Injection?
The projected CAGR is approximately 1.6%.
2. Which companies are prominent players in the Pemetrexed Disodium for Injection?
Key companies in the market include Lilly, Amneal Pharmaceuticals, APOTEX, Fresenius Kabi, Sandoz, Baxter, Biocon, Waverley Pharma, Accord Healthcare, Pfizer (Hospira), Dr. Reddy's Laboratories, Nang Kuang Pharmaceutical, Eugia Pharma, Zydus Lifesciences, Jiangsu Hansoh Pharmaceutical, Qilu Pharmaceutical, Sichuan Huiyu Pharmaceutical, Kelun Pharmaceutical, Yangtze River Pharmaceutical Group, Jiangsu Aosaikang Pharmaceutical, Zhendong Group, Lianyungang Jaripharm Pharmaceutical, Jiangsu Simcere Pharmaceutical, Suzhou Erye Pharmaceutical, Shanghai Chemo Wanbang Biopharma, Hainan Jinrui Pharmaceutical, Dezhou Deyao Pharmaceutical, Nanjing Pharmaceutical Factory, Beijing Xiehe Pharmaceutical, Suzhou Thery Pharmaceutical.
3. What are the main segments of the Pemetrexed Disodium for Injection?
The market segments include Application, Types.
4. Can you provide details about the market size?
The market size is estimated to be USD 2.38 billion as of 2022.
5. What are some drivers contributing to market growth?
N/A
6. What are the notable trends driving market growth?
N/A
7. Are there any restraints impacting market growth?
N/A
8. Can you provide examples of recent developments in the market?
N/A
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 3350.00, USD 5025.00, and USD 6700.00 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in billion and volume, measured in K.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Pemetrexed Disodium for Injection," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Pemetrexed Disodium for Injection report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Pemetrexed Disodium for Injection?
To stay informed about further developments, trends, and reports in the Pemetrexed Disodium for Injection, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence